idebenone has been researched along with Disease Exacerbation in 12 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Friedreich ataxia is an inherited disorder characterized by degeneration of the peripheral and central nervous system and hypertrophic cardiomyopathy." | 6.82 | Clinical Experience With Deferiprone Treatment for Friedreich Ataxia. ( Arad, M; Cabantchik, I; Elincx-Benizri, S; Freimark, D; Glik, A; Hassin-Baer, S; Kozlova, E; Merkel, D, 2016) |
| "Idebenone was well tolerated but did not inhibit disability progression or CNS tissue destruction." | 2.94 | Idebenone does not inhibit disability progression in primary progressive MS. ( Bielekova, B; Komori, M; Kosa, P; Leinonen, M; Masvekar, R; Phillips, J; Sandford, M; Wichman, A; Wu, T, 2020) |
| "Friedreich ataxia is an inherited disorder characterized by degeneration of the peripheral and central nervous system and hypertrophic cardiomyopathy." | 2.82 | Clinical Experience With Deferiprone Treatment for Friedreich Ataxia. ( Arad, M; Cabantchik, I; Elincx-Benizri, S; Freimark, D; Glik, A; Hassin-Baer, S; Kozlova, E; Merkel, D, 2016) |
| "Idebenone treatment resulted in a trend (p=0." | 2.76 | Idebenone as a novel, therapeutic approach for Duchenne muscular dystrophy: results from a 12 month, double-blind, randomized placebo-controlled trial. ( Buyse, GM; Ceulemans, B; de Groot, IJ; Goemans, N; Meier, T; Mertens, L; Schara, U; Thijs, D; van den Hauwe, M, 2011) |
| "Although the phenotype is well known, disease progression has not been evaluated in a prospective manner." | 2.73 | Neurological, cardiological, and oculomotor progression in 104 patients with Friedreich ataxia during long-term follow-up. ( Béraud, AS; Brice, A; Charles, P; Dürr, A; Gasparini, F; Koenig, M; Le Ber, I; Mallet, A; Pousset, F; Ribaï, P; Rivaud-Pechoux, S; Schmitt, M; Tanguy, ML, 2007) |
| "Primary outcome measures were the Alzheimer's Disease Assessment Scale-Cognitive Subcomponent (ADAS-Cog) and a Clinical Global Impression of Change (CGIC)." | 2.71 | Idebenone treatment fails to slow cognitive decline in Alzheimer's disease. ( Berg, J; Ernstrom, K; Grundman, M; Margolin, R; Pfeiffer, E; Thal, LJ; Thomas, RG; Weiner, MF; Zamrini, E, 2003) |
| "The dystrophinopathies include Duchenne muscular dystrophy (DMD), Becker muscular dystrophy (BMD), and X-linked dilated cardiomyopathy (XLDCM)." | 2.58 | Interventions for preventing and treating cardiac complications in Duchenne and Becker muscular dystrophy and X-linked dilated cardiomyopathy. ( Bourke, JP; Bueser, T; Quinlivan, R, 2018) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (33.33) | 29.6817 |
| 2010's | 7 (58.33) | 24.3611 |
| 2020's | 1 (8.33) | 2.80 |
| Authors | Studies |
|---|---|
| Kosa, P | 1 |
| Wu, T | 1 |
| Phillips, J | 1 |
| Leinonen, M | 1 |
| Masvekar, R | 1 |
| Komori, M | 1 |
| Wichman, A | 1 |
| Sandford, M | 1 |
| Bielekova, B | 1 |
| Bourke, JP | 1 |
| Bueser, T | 1 |
| Quinlivan, R | 1 |
| Orssaud, C | 1 |
| Bidot, S | 1 |
| Lamirel, C | 1 |
| Brémond Gignac, D | 1 |
| Touitou, V | 1 |
| Vignal, C | 1 |
| Elincx-Benizri, S | 1 |
| Glik, A | 1 |
| Merkel, D | 1 |
| Arad, M | 1 |
| Freimark, D | 1 |
| Kozlova, E | 1 |
| Cabantchik, I | 1 |
| Hassin-Baer, S | 1 |
| Dolgin, E | 1 |
| Buyse, GM | 1 |
| Goemans, N | 1 |
| van den Hauwe, M | 1 |
| Thijs, D | 1 |
| de Groot, IJ | 1 |
| Schara, U | 1 |
| Ceulemans, B | 1 |
| Meier, T | 1 |
| Mertens, L | 1 |
| García-Giménez, JL | 1 |
| Gimeno, A | 1 |
| Gonzalez-Cabo, P | 1 |
| Dasí, F | 1 |
| Bolinches-Amorós, A | 1 |
| Mollá, B | 1 |
| Palau, F | 1 |
| Pallardó, FV | 1 |
| Anheim, M | 1 |
| Mariani, LL | 1 |
| Calvas, P | 1 |
| Cheuret, E | 1 |
| Zagnoli, F | 1 |
| Odent, S | 1 |
| Seguela, C | 1 |
| Marelli, C | 1 |
| Fritsch, M | 1 |
| Delaunoy, JP | 1 |
| Brice, A | 2 |
| Dürr, A | 2 |
| Koenig, M | 2 |
| Thal, LJ | 1 |
| Grundman, M | 1 |
| Berg, J | 1 |
| Ernstrom, K | 1 |
| Margolin, R | 1 |
| Pfeiffer, E | 1 |
| Weiner, MF | 1 |
| Zamrini, E | 1 |
| Thomas, RG | 1 |
| Auré, K | 1 |
| Benoist, JF | 1 |
| Ogier de Baulny, H | 1 |
| Romero, NB | 1 |
| Rigal, O | 1 |
| Lombès, A | 1 |
| Ribaï, P | 1 |
| Pousset, F | 1 |
| Tanguy, ML | 1 |
| Rivaud-Pechoux, S | 1 |
| Le Ber, I | 1 |
| Gasparini, F | 1 |
| Charles, P | 1 |
| Béraud, AS | 1 |
| Schmitt, M | 1 |
| Mallet, A | 1 |
| Carelli, V | 1 |
| Valentino, ML | 1 |
| Liguori, R | 1 |
| Meletti, S | 1 |
| Vetrugno, R | 1 |
| Provini, F | 1 |
| Mancardi, GL | 1 |
| Bandini, F | 1 |
| Baruzzi, A | 1 |
| Montagna, P | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase IIa Double Blind, Randomised, Placebo Controlled, Single Centre Study at the University of Leuven to Assess the Efficacy and Tolerability of Idebenone in 8 - 16 Year Old Males With Cardiac Dysfunction Associated With Duchenne Muscular Dystrophy[NCT00654784] | Phase 2 | 21 participants (Actual) | Interventional | 2005-10-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"Assessing the peak systolic radial strain of the left ventricle inferolateral wall is used to characterize the cardiac involvement in the DMD patients.~Color Doppler Myocardial Imaging technique is used to quantify regional myocardial function.~The cardiac involvement in DMD is characterized by degeneration, atrophy and fibrosis of the myocardium, leading to dilated cardiomyopathy. The process begins in the posterolateral wall of the left ventricle, with septal involvement appearing at later stages." (NCT00654784)
Timeframe: baseline and Week 52
| Intervention | % change in peak systolic (Mean) |
|---|---|
| Idebenone 450 mg/ Day | 104.4 |
| Placebo | 28.9 |
1 review available for idebenone and Disease Exacerbation
| Article | Year |
|---|---|
Interventions for preventing and treating cardiac complications in Duchenne and Becker muscular dystrophy and X-linked dilated cardiomyopathy.
Topics: Adolescent; Adult; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antih | 2018 |
5 trials available for idebenone and Disease Exacerbation
| Article | Year |
|---|---|
Idebenone does not inhibit disability progression in primary progressive MS.
Topics: Axons; Biomarkers; Disease Progression; Double-Blind Method; Humans; Multiple Sclerosis; Multiple Sc | 2020 |
Clinical Experience With Deferiprone Treatment for Friedreich Ataxia.
Topics: Adolescent; Adult; Antioxidants; Deferiprone; Disease Progression; Double-Blind Method; Drug Therapy | 2016 |
Idebenone as a novel, therapeutic approach for Duchenne muscular dystrophy: results from a 12 month, double-blind, randomized placebo-controlled trial.
Topics: Adolescent; Antioxidants; Child; Disease Progression; Dose-Response Relationship, Drug; Double-Blind | 2011 |
Idebenone treatment fails to slow cognitive decline in Alzheimer's disease.
Topics: Aged; Alzheimer Disease; Benzoquinones; Cognition Disorders; Disease Progression; Double-Blind Metho | 2003 |
Neurological, cardiological, and oculomotor progression in 104 patients with Friedreich ataxia during long-term follow-up.
Topics: Adolescent; Adult; Aged; Antioxidants; Benzoquinones; Disease Progression; Echocardiography; Electro | 2007 |
6 other studies available for idebenone and Disease Exacerbation
| Article | Year |
|---|---|
[Raxone in the Leber optical neuropathy: Parisian experience].
Topics: Adolescent; Adult; Disease Progression; Female; Humans; Male; Middle Aged; Optic Atrophy, Hereditary | 2019 |
Therapies: Progressive steps.
Topics: Animals; Antibodies, Monoclonal, Humanized; Antigens, CD20; Azetidines; B-Lymphocytes; Benzamides; B | 2016 |
Differential expression of PGC-1α and metabolic sensors suggest age-dependent induction of mitochondrial biogenesis in Friedreich ataxia fibroblasts.
Topics: Adenosine Triphosphate; Adolescent; Adult; Aging; Alleles; AMP-Activated Protein Kinases; Antioxidan | 2011 |
Exonic deletions of FXN and early-onset Friedreich ataxia.
Topics: Adult; Antioxidants; Cardiomyopathies; Disease Progression; Electromyography; Exons; Family Health; | 2012 |
Progression despite replacement of a myopathic form of coenzyme Q10 defect.
Topics: Benzoquinones; Carnitine; Cerebellar Ataxia; Cerebellum; Child, Preschool; Disease Progression; Drug | 2004 |
Leber's hereditary optic neuropathy (LHON/11778) with myoclonus: report of two cases.
Topics: Adult; Anti-Inflammatory Agents; Antioxidants; Benzoquinones; Biopsy; Disease Progression; Electroen | 2001 |